DWK Life Sciences increases glass vial production capacity to meet demand
Best-in-class automation, robotics and state-of-the-art touchless production lines that provide the cleanliness required for parenteral packaging containers.
DWK Life Sciences, a manufacturer and supplier of premium glass, plastics, custom configurations and packaging solutions, has expanded and modernized its glass vial production facility in Rockwood, TN to meet the increased borosilicate glass vial market demand for vaccines, diagnostics and therapeutics.
The company combined new equipment installations with significant improvements to existing equipment to more than double production capacity.
With a substantial capital investment into the facility, DWK Life Sciences now operates fully automated production lines and a centralized Class 8 certified cleanroom.
Specific upgrades to the manufacturing capabilities include the addition of new automated tube loaders with vertical loading capabilities.
Using state-of-the-art, automated manufacturing processes and Class 8 Clean Room robotic packing, tubular glass vials and tubes are produced in our ISO 9001 certified facility, operated under AQL methods of inspection. The plant enhancements is enabling the company to deliver increased production output, both in product quantity and quality.
“By converting to state-of-the-art lines, complete with dimensional and cosmetic vision inspection equipment, we’ve increased productivity in the plant and are delivering industry leading quality for glass vials,” said Rick Schwartz, Senior Vice President of Marketing and Sales at DWK Life Sciences.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.